Skip to main content
. 2022 Feb 25;13:848813. doi: 10.3389/fphar.2022.848813

FIGURE 6.

FIGURE 6

ECH regulated IL-6/JAK2/STAT3 signaling in LPS-induced BV2 cells. (A) BV2 microglial cells were pretreated with ECH (5, 10, and 20 mg/L) for 2 h and exposed to LPS (1 μg/ml) for 6h; then, the expression levels of IL-6, p-JAK2, JAK2, p-STAT3 (tyr705), p-STAT3 (ser727), STAT3, and BDNF were measured with Western blot. (B) Western blot analysis for IL-6. (C) Western blot analysis for p-JAK2/JAK. (D) Western blot analysis for p-STAT3/STAT3. (E) Western blot analysis for p-STAT3 (ser727)/STAT3. (F) Western blot analysis for BDNF. (G) Immunofluorescence staining for p-STAT3 (tyr705) (red) in ECH (20 mg/L, 2 h) pretreated BV2 cells and then exposed to LPS (1 μg/ml) for 6 h. (H) BV2 cells were pretreated with S3I-201 (STAT3 inhibitor, 100 µM) for 24 h and then treated with ECH (20 mg/L) for 2 h and induced by LPS (1 μg/ml) for 6 h. The expression levels of IL-6, p-JAK2, JAK2, p-STAT3 (tyr705), p-STAT3 (ser727), STAT3, and BDNF are shown under S3I-201 treatment. (I) Western blot analysis for IL-6. (J) Western blot analysis for p-JAK2/JAK. (K) Western blot analysis for p-STAT3 (tyr705)/STAT3. (L) Western blot analysis for p-STAT3 (ser727)/STAT3. (M) Western blot analysis for BDNF. Values are presented as the mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001.